Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Investigator-initiated Clinical Trial of MIKE-1 With Gemcitabine and Nab-paclitaxel Combination Therapy for Unresectable Pancreatic Cancer

NCT05064618 is registered in ClinicalTrials.gov with Nagoya University as lead sponsor.

NCT NCT05064618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05064618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Investigator-initiated Clinical Trial of MIKE-1 With Gemcitabine and Nab-paclitaxel Combination Therapy for Unresectable Pancreatic Cancer
Lead sponsor
Nagoya University
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 23, 2021
Completion date
April 30, 2025
Enrollment
55 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer